Table 1—

Baseline patient characteristics

PlaceboTadalafil 10 mgTadalafil 20 mgOverall
n717372216
Age (years)55.8 ± 9.155.9 ± 8.855.5 ± 9.055.7 ± 9.0
Race
 White70 (98.6)73 (100)72 (100)215 (99.5)
 Black1 (1.4)001 (0.5)
Diabetes duration (years)11.9 ± 9.611.9 ± 9.411.2 ± 9.511.7 ± 9.5
Type 1 diabetes8 (11.3)8 (11.0)4 (5.6)20 (9.3)
Type 2 diabetes63 (88.7)65 (89.0)68 (94.4)196 (90.7)
Diabetes control
 Good: HbA1c <7.0%15 (21.1)13 (17.8)12 (16.7)40 (18.5)
 Fair: HbA1c 7.0–9.5%42 (59.2)51 (69.9)43 (59.7)136 (63.0)
 Poor: HbA1c >9.5%14 (19.7)9 (12.3)17 (23.6)40 (18.5)
Microvascular complications*14 (19.7)15 (20.5)19 (26.4)48 (22.2)
Current diabetic therapy
 Insulin only32 (45.1)26 (35.6)20 (27.8)78 (36.1)
 Oral only29 (40.8)32 (43.8)39 (54.2)100 (46.3)
 Insulin + oral7 (9.9)9 (12.3)6 (8.3)22 (10.2)
 None3 (4.2)6 (8.2)7 (9.7)16 (7.4)
IIEF erectile function domain score12.1 ± 6.112.9 ± 6.911.5 ± 5.612.2 ± 6.2
ED duration >1 year (%)66 (93.0)68 (93.2)67 (93.1)201 (93.1)
  • Data are means ± SE or n (%).

  • *

    * Patients with microvascular complications had a history of diabetic retinopathy, laser treatment for diabetic eye disease, or a urine microalbumin-to-creatinine ratio >3.0 at visit 1.